Status:
RECRUITING
Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients
Lead Sponsor:
University Hospital Ostrava
Conditions:
Arterial Hypertension
Eligibility:
All Genders
18-100 years
Brief Summary
Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment...
Detailed Description
Arterial hypertension and diabetes are the most common cause of chronic kidney disease. Commonly used parameters for the evaluation of renal function (plasma creatinine, estimated glomerular filtratio...
Eligibility Criteria
Inclusion
- Arterial hypertension treated by at least one antihypertensive agent
Exclusion
- Diabetes mellitus of any type, defined as fasting glucose \>7,0 mmol/l or any glycemia \>11,0 mmol/l, or HbA1c\>48 mmol/mol
- Decompensated arterial hypertension defined as office blood pressure \>180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM)
- Patient with renal replacement therapy
- Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening
- Acute infection defined as C-Reactive Protein (CRP) \>50 mg/l
- Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) \>10 µkat/l
- Terminal incurable illness
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05963126
Start Date
July 1 2023
End Date
December 31 2026
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ostrava, - Department of Internal Medicine and Cardiology
Ostrava, Czech Republic, Czechia, 70852